Efficacy of Efgartigimod in Treating Active CIDP

In a large, multistage study, efgartigimod injections resulted in rapid clinical improvements and, in responders, reduced the likelihood of relapse by more than half.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is characterized by progressive or relapsing, and often debilitating, sensory-motor deficits. Pathogenic immunoglobulin G (IgG) autoantibodies causing demyelination and/or conduction block have been implicated in CIDP pathogenesis. Efgartigimod alfa is a neonatal Fc receptor (FcRn) inhibitor that reduces circulating IgG; it is approved to treat myasthenia gravis. Investigators now report an industry-funded, international, multistage trial of efgartigimod in adults with active CIDP who worsened before study entry or relapsed after discontinuing prior treatments during a run-in phase.

In stage A (open-label), 322 patients were treated weekly, for up to 12 weeks, with subcutaneous…

Reviewing Author

Leana Doherty, MD

Disclosures

Editorial BoardsNeurohospitalist Society; InterACTN (Annals of Clinical and Translational Neurology)

Leana Doherty, MD

Disclosures

Editorial BoardsNeurohospitalist Society; InterACTN (Annals of Clinical and Translational Neurology)

Efficacy of Efgartigimod in Treating Active CIDP

Topics

Reviewing Author